Novo Nordisk Releases Data Showing Ozempic For Diabetes Slows Kidney Disease Progression

Novo Nordisk A/S’s NVO shared data Friday on its kidney outcomes trial, FLOW. The trial evaluated once-weekly injectable Ozempic for the treatment of type 2 diabetes.

The FLOW (Evaluate Renal Function with Semaglutide Once Weekly) study included 3,533 patients with a median follow-up period of 3.4 years.

In March, the company released headline data demonstrating a 24% reduction in kidney disease progression and cardiovascular and kidney death.

Also Read: Novo Nordisk’s Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review.

The data was shared at the European Renal Association Congress.

Detailed data showed that secondary endpoints also showed significant improvements with semaglutide. Specifically, the total estimated glomerular filtration rate (eGFR) slope was 1.16 ml/min/1.73m2/year slower, the risk of major cardiovascular events was decreased by 18%, and the risk of all-cause mortality was reduced by 20%.

Vlado Perkovic, a professor, presented the results for the first time today at the 61st ERA Congress.

“The use of semaglutide in people with type 2 diabetes and chronic kidney disease can lower the risk of major kidney outcomes and reduce the risk of cardiovascular events, cardiovascular death and all-cause death,” Perkovic said. “These benefits signify a profound clinical impact saving kidneys, hearts and lives, for patients with type 2 diabetes and chronic kidney disease. Additionally, the reassuring safety findings further support the strong potential value of semaglutide in this population.”

The findings offer promise in reshaping treatment strategies for individuals at high risk of diabetes-related complications, offering a new avenue for kidney and cardiovascular protection, Perkovic added.

Price Action: NVO shares are down 0.67% at $134.66 at last check Friday.

Read Next: The Ozempic Diet: Nestle Launches $5 Pizza For Weight Loss Drug Users.

Image: Shutterstock